The Changing Landscape for Stroke\ua0Prevention in AF: Findings From the GLORIA-AF Registry Phase 2

Background GLORIA-AF (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation) is a prospective, global registry program describing antithrombotic treatment patterns in patients with newly diagnosed nonvalvular atrial fibrillation at risk of stroke. Phase 2 began when dabigatran, the first non\u2013vitamin K antagonist oral anticoagulant (NOAC), became available. Objectives This study sought to describe phase 2 baseline data and compare these with the pre-NOAC era collected during phase 1. Methods During phase 2, 15,641 consenting patients were enrolled (November 2011 to December 2014); 15,092 were eligible. This pre-specified cross-sectional analysis describes eligible patients\u2019 baseline characteristics. Atrial fibrillation disease characteristics, medical outcomes, and concomitant diseases and medications were collected. Data were analyzed using descriptive statistics. Results Of the total patients, 45.5% were female; median age was 71 (interquartile range: 64, 78) years. Patients were from Europe (47.1%), North America (22.5%), Asia (20.3%), Latin America (6.0%), and the Middle East/Africa (4.0%). Most had high stroke risk (CHA2DS2-VASc [Congestive heart failure, Hypertension, Age  6575 years, Diabetes mellitus, previous Stroke, Vascular disease, Age 65 to 74 years, Sex category] score  652; 86.1%); 13.9% had moderate risk (CHA2DS2-VASc = 1). Overall, 79.9% received oral anticoagulants, of whom 47.6% received NOAC and 32.3% vitamin K antagonists (VKA); 12.1% received antiplatelet agents; 7.8% received no antithrombotic treatment. For comparison, the proportion of phase 1 patients (of N = 1,063 all eligible) prescribed VKA was 32.8%, acetylsalicylic acid 41.7%, and no therapy 20.2%. In Europe in phase 2, treatment with NOAC was more common than VKA (52.3% and 37.8%, respectively); 6.0% of patients received antiplatelet treatment; and 3.8% received no antithrombotic treatment. In North America, 52.1%, 26.2%, and 14.0% of patients received NOAC, VKA, and antiplatelet drugs, respectively; 7.5% received no antithrombotic treatment. NOAC use was less common in Asia (27.7%), where 27.5% of patients received VKA, 25.0% antiplatelet drugs, and 19.8% no antithrombotic treatment. Conclusions The baseline data from GLORIA-AF phase 2 demonstrate that in newly diagnosed nonvalvular atrial fibrillation patients, NOAC have been highly adopted into practice, becoming more frequently prescribed than VKA in Europe and North America. Worldwide, however, a large proportion of patients remain undertreated, particularly in Asia and North America. (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients With Atrial Fibrillation [GLORIA-AF]; NCT01468701

2015 Brainhack Proceedings

Table of contents I1 Introduction to the 2015 Brainhack Proceedings R. Cameron Craddock, Pierre Bellec, Daniel S. Margules, B. Nolan Nichols, Jörg P. Pfannmöller A1 Distributed collaboration: the case for the enhancement of Brainspell’s interface AmanPreet Badhwar, David Kennedy, Jean-Baptiste Poline, Roberto Toro A2 Advancing open science through NiData Ben Cipollini, Ariel Rokem A3 Integrating the Brain Imaging Data Structure (BIDS) standard into C-PAC Daniel Clark, Krzysztof J. Gorgolewski, R. Cameron Craddock A4 Optimized implementations of voxel-wise degree centrality and local functional connectivity density mapping in AFNI R. Cameron Craddock, Daniel J. Clark A5 LORIS: DICOM anonymizer Samir Das, Cécile Madjar, Ayan Sengupta, Zia Mohades A6 Automatic extraction of academic collaborations in neuroimaging Sebastien Dery A7 NiftyView: a zero-footprint web application for viewing DICOM and NIfTI files Weiran Deng A8 Human Connectome Project Minimal Preprocessing Pipelines to Nipype Eric Earl, Damion V. Demeter, Kate Mills, Glad Mihai, Luka Ruzic, Nick Ketz, Andrew Reineberg, Marianne C. Reddan, Anne-Lise Goddings, Javier Gonzalez-Castillo, Krzysztof J. Gorgolewski A9 Generating music with resting-state fMRI data Caroline Froehlich, Gil Dekel, Daniel S. Margulies, R. Cameron Craddock A10 Highly comparable time-series analysis in Nitime Ben D. Fulcher A11 Nipype interfaces in CBRAIN Tristan Glatard, Samir Das, Reza Adalat, Natacha Beck, Rémi Bernard, Najmeh Khalili-Mahani, Pierre Rioux, Marc-Étienne Rousseau, Alan C. Evans A12 DueCredit: automated collection of citations for software, methods, and data Yaroslav O. Halchenko, Matteo Visconti di Oleggio Castello A13 Open source low-cost device to register dog’s heart rate and tail movement Raúl Hernández-Pérez, Edgar A. Morales, Laura V. Cuaya A14 Calculating the Laterality Index Using FSL for Stroke Neuroimaging Data Kaori L. Ito, Sook-Lei Liew A15 Wrapping FreeSurfer 6 for use in high-performance computing environments Hans J. Johnson A16 Facilitating big data meta-analyses for clinical neuroimaging through ENIGMA wrapper scripts Erik Kan, Julia Anglin, Michael Borich, Neda Jahanshad, Paul Thompson, Sook-Lei Liew A17 A cortical surface-based geodesic distance package for Python Daniel S Margulies, Marcel Falkiewicz, Julia M Huntenburg A18 Sharing data in the cloud David O’Connor, Daniel J. Clark, Michael P. Milham, R. Cameron Craddock A19 Detecting task-based fMRI compliance using plan abandonment techniques Ramon Fraga Pereira, Anibal Sólon Heinsfeld, Alexandre Rosa Franco, Augusto Buchweitz, Felipe Meneguzzi A20 Self-organization and brain function Jörg P. Pfannmöller, Rickson Mesquita, Luis C.T. Herrera, Daniela Dentico A21 The Neuroimaging Data Model (NIDM) API Vanessa Sochat, B Nolan Nichols A22 NeuroView: a customizable browser-base utility Anibal Sólon Heinsfeld, Alexandre Rosa Franco, Augusto Buchweitz, Felipe Meneguzzi A23 DIPY: Brain tissue classification Julio E. Villalon-Reina, Eleftherios Garyfallidi